Extension of Time to File SOU

TRULICITY

Eli Lilly and Company

Trademark/Service Extension of Time

PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)

Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 85183667
LAW OFFICE ASSIGNED LAW OFFICE 114
MARK SECTION
MARK TRULICITY
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
LITERAL ELEMENT TRULICITY
OWNER SECTION
NAME Eli Lilly and Company
STREET Lilly Corporate Center
CITY Indianapolis
STATE Indiana
ZIP/POSTAL CODE 46285
COUNTRY United States
PHONE 317-276-9624
FAX 317-276-1919
EMAIL XXXX
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety spectrum disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis; pharmaceutical preparations for use in the treatment of autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for veterinary use
GOODS OR SERVICES DELETED FROM THE APPLICATION anxiety, spectrum, pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis;
GOODS OR SERVICES FOR WHICH APPLICANT HAS A CONTINUED BONA FIDE INTENTION, AND IS ENTITLED, TO USE Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, bone and skeletal diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for veterinary use
EXTENSION SECTION
EXTENSION NUMBER 2
ONGOING EFFORT product or service research or development
ALLOWANCE MAIL DATE 06/07/2011
STATEMENT OF USE NO
PAYMENT SECTION
NUMBER OF CLASSES 1
SUBTOTAL AMOUNT 150
TOTAL AMOUNT 150
SIGNATURE SECTION
SIGNATURE /reljr44/
SIGNATORY'S NAME Robert E. Lee, Jr.
SIGNATORY'S POSITION Assistant General Patent Counsel
DATE SIGNED 04/25/2012
SIGNATORY'S PHONE NUMBER 317 276 9624
FILING INFORMATION
SUBMIT DATE Wed Apr 25 18:20:52 EDT 2012
TEAS STAMP USPTO/ESU-XX.XXX.XX.XX-20
120425182052942409-851836
67-490bded3d245236bcf0dce
cef6276f8d631-DA-9638-201
20425172110109611



PTO Form 1581 (Rev 9/2005)
OMB No. 0651-0054 (Exp. 10/31/2017)


SOU Extension Request
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:

MARK: TRULICITY
SERIAL NUMBER: 85183667

The applicant, Eli Lilly and Company, having an address of
      Lilly Corporate Center
      Indianapolis, Indiana 46285
      United States
requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application.    The Notice of Allowance mailing date was 06/07/2011.

For International Class 005:
Current identification: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, anxiety, bone and skeletal diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety spectrum disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis; pharmaceutical preparations for use in the treatment of autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for veterinary use

This filing does NOT cover the following goods/services listed in either the application or Notice of Allowance or as subsequently modified for this specific class; these goods/services are permanently deleted from this application: anxiety, spectrum, pharmaceutical preparations for use in the treatment of diabetes; pharmaceutical preparations for use in the treatment of rheumatoid arthritis; pharmaceutical preparations for use in the treatment of Crohn's disease, systemic lupus erythematosus, and ankylosing spondylitis disease; pharmaceutical preparations for use in the treatment of psoriasis and psoriatic arthritis;

For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this specific class: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorders, bone and skeletal diseases and disorders, blood disorders, cancer, cardiovascular diseases, cholesterol disorders, central nervous system diseases and disorders, diabetes, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, liver diseases and disorders, kidney diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, reproductive system diseases and disorders, urological disorders, dyslipidemia, sleep disorders, migraines, metabolic diseases and disorders; antipsychotics; antidepressants; pharmaceutical preparations for use in the treatment of anxiety disorders, atherosclerosis and Alzheimer's; pharmaceutical preparations for use in the treatment of autoimmune disorders; Veterinary preparations for companion animals in the treatment of weight loss, obesity, urine spraying, chronic pain, gastrointestinal disorders, neurodegenerative disorders, parasitic infestations, neurological disorders, anxiety, hypertension, dermatitis, cancer, anemia associated with chronic renal failure, fleas, pain associated with orthopedic and soft tissue surgery, chronic kidney disease, and emesis; preparations for destroying vermin, namely, insecticides for use with livestock and livestock premises; veterinary preparations for the treatment, control and symptomatic relief of infectious and metabolic diseases of livestock; dietary food supplements for animals; antibacterial pharmaceuticals; production enhancement for livestock, namely, medicated feed and medicated water additives; medicated feed additives and medicated water additives for animals; diagnostic agents, preparations, and substances to identify pathogens or residues of biological interest for veterinary use

This is the second extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension request: product or service research or development



A fee payment in the amount of $150 will be submitted with the form, representing payment for 1 class.


Declaration

The undersigned, being hereby warned that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. Section 1001, and that such willful false statements may jeopardize the validity of the form or any resulting registration, declares that he/she is properly authorized to execute this form on behalf of the applicant; he/she believes the applicant to be the owner of the trademark/service mark sought to be registered; and that all statements made of his/her own knowledge are true; and that all statements made on information and belief are believed to be true.


Signature: /reljr44/      Date Signed: 04/25/2012
Signatory's Name: Robert E. Lee, Jr.
Signatory's Position: Assistant General Patent Counsel
Signatory's Phone: 317 276 9624

RAM Sale Number: 9638
RAM Accounting Date: 04/26/2012

Serial Number: 85183667
Internet Transmission Date: Wed Apr 25 18:20:52 EDT 2012
TEAS Stamp: USPTO/ESU-XX.XXX.XX.XX-20120425182052942
409-85183667-490bded3d245236bcf0dcecef62
76f8d631-DA-9638-20120425172110109611



Extension of Time to File SOU [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed